Modulating Tumor Immunity & Resistance Mechanisms by Integrating Radioligand Therapy with Immune Checkpoint & Cellular Immunotherapies
- Characterizing RLT-induced immune modulation and its role in tumor sensitization and resistance
- Evaluating preclinical combinations of RLT with immune checkpoint inhibitors, CAR-T cells, and emerging immunotherapies
- Leveraging synergistic immune-radiobiological mechanisms to enhance depth and durability of response